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Purpose: To determine whether multiparametric MRI could help predict the diagnosis of low-risk
prostate cancer (PCA).
Methods: We retrospectively analyzed consecutive 623 patients with PCA who underwent multi-
parametric MRI before radical prostatectomy(RP). High-resolution T1- and T2-weighted, diffusion-
weighted, and dynamic precontrast and postcontrast image sequences were obtained for each patient. Of
the 623 patients, 177(28.4%) exhibited non visible tumors on MRI of clinical stage T1c. The imaging re-
sults were compared with the pathological ﬁndings with respect to both stage and Gleason scores (GS).
Results: Of the 177 prostatectomy patients with non visible tumors on MRI, pathological ﬁndings
resulted in the upgrading of 49(27.7%) patients to a sum of GS 7 or more. 101(57.1%) patients exhibited
tumor volumes greater than 0.5cc. The biochemical recurrence rate was signiﬁcantly higher in the
pathological upgraded group compared with the nonupgraded group after a mean follow-up time of 29
months. In the multiple logistic analysis, non visible tumor on MRI was not a signiﬁcant predictor of low-
risk PCA.
Conclusions: Even though cancer foci were not visualized by postbiopsy MRI, the pathological tumor
volumes and extent of GS upgrading were relatively high. Therefore, nonvisible tumors by multi-
parametric MRI do not appear to be predictive of low-risk PCA.
Copyright © 2015 Asian Paciﬁc Prostate Society, Published by Elsevier. All rights reserved.1. Introduction
The detection of low-risk prostate cancer (PCA) has increased as
cancer screening programs and detection mechanisms have
improved.1 Since the number of patients diagnosed with low-risk
PCA has increased in recent times, the ability to precisely localize
tumor foci within the prostate has become an important goal.
Accurately identifying the positions of PCA tumors would increase
staging accuracy, improve patient selection for active surveillance
(AS), and facilitate treatment planning.2
A growing body of evidence indicates that AS is the most
suitable approach for a select group of men with low-risk PCA.3
However, pretreatment diagnosis of low-risk PCA is oftenYonsei University College of
, Gangnam-gu, Seoul, South
iﬁc Prostate Society, Published bydifﬁcult since PCA is a multifocal, heterogeneous disease.4 More-
over, the current criteria used to deﬁne low-risk PCA cannot
reliably determine whether AS is the best treatment option for
each patient. Some studies have reported that even low-risk PCA
may demonstrate disease upgrading or upstaging.5,6 Even known
indicators of the severity of PCA, such as prostate-speciﬁc antigen
(PSA) kinetics or initial biopsy results at the time of PCA diagnosis,
do not reliably predict adverse pathology when men are moni-
tored by AS.7 Therefore, imaging techniques have played an
increasingly important role in the management of localized PCA.
However, no imaging modality presently available is able to
measure the actual cancer volume.8 Moreover, no current criteria
for AS reliably includes clinical staging based on the imaging
modality. Therefore, the aim of the present study was to deter-
mine whether multiparametric magnetic resonance imaging
(MRI) could help predict the diagnosis of low-risk PCA. Focusing
on nonvisible tumors on multiparametric MRI of clinical stage T1c,
we assessed the clinicopathological relationships between the
biopsy and pathological results.Elsevier. All rights reserved.
Table 1
Pathological ﬁndings from analyses of radical prostatectomy specimens
from patients preoperatively classiﬁed as clinical stage T1c.
Findings No. of patients (%)
Total no. of patients 177
Pathological Gleason score
Upgraded 49 (27.9)
Downgraded 26 (14.7)
Identical 102 (57.6)
Stage
T2a 53 (29.9)
T2b 51 (28.7)
T2c 22 (12.4)
T3 51 (29.0)
Positive surgical margin 62 (35.5)
Tumor volume (cc)
0e0.5 76 (42.9)
>0.5 101 (57.1)
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We retrospectively analyzed 623 consecutive patients with PCA
who underwent multiparametric MRI before radical prostatectomy
(RP) at our institution. Patients who had undergone prostate biopsy
at another institution, hormone therapy, or radiation therapy
before the RP were excluded from the study.
All patients underwent a transrectal, ultrasound-guided 12-core
needle biopsy. In all patients, the serum PSA level was obtained
before digital rectal examination and transrectal ultrasonography.
Clinical staging was performed according to the TNM staging sys-
tem, and the ellipsoid formula was used to derive the prostate
volume via transrectal ultrasonography.
For all clinical staging protocols, all patients underwent imaging
using a 3.0T MRI system (Intera Achieva 3.0T, Phillips Medical
System, Best, The Netherlands) equipped with a phased array coil
(6-channel) before RP. All patients also underwent diffusion
weighted-MRI, in addition to the routine prostate MRI protocol
used at our institution. Two b values (0 and 1,000) were used, and
diffusion restriction was quantiﬁed using ADC mapping. T2-
weighted images were acquired in three orthogonal planes (axial,
sagittal, and coronal). Dynamic contrast-enhanced MRI was also
performed. All images were retrospectively reviewed by two
experienced uroradiologists who were blinded to biopsy results
and who conducted a consensus review of the MRI of all patients.
Of the 623 patients included in the analysis, 177 (28.4%) had a
nonvisible tumor on MRI of clinical stage T1c. The imaging results
were then compared with the pathological ﬁndings with respect to
stage and Gleason score (GS). All biopsy and RP specimens were
reviewed by a single genitourinary pathologist, and all biopsy cores
were individually labeled. For each biopsy protocol, the number of
cores containing tumor tissue, the total length of tissue sampled, the
total length of the cancer detected, and the GS were determined.
Transverse whole-mount step section specimens were obtained at
3e4mm intervals on a parallel plane, and the genitourinary
pathologist followed a standardized processing and reporting pro-
tocol.9 Tumor volume (cc) was evaluated by visual estimation. Tu-
mor areawasmeasured in thex and y diameters, and the tumor area
was then multiplied by the tumor depth, as determined by the
presence of the tumor in subsequent sections and the thicknesses of
those sections. The total sum of all tumor foci corresponded to the
estimated tumor volume. To achieve objective interpretation,
another reviewer integrated the radiology and pathology results.
Clinicopathologic outcomes were compared using the Chi-
square test and independent t test for categorical and continuous
variables, respectively. Low-risk PCA was deﬁned as an organ-
conﬁned, postoperative GS 6 tumor with a volume less than
0.5 cm3. For AS, the criteria outlined in the Prostate Cancer Research
International: Active Surveillance protocol were used. The inclusion
criteria for Prostate Cancer Research International: Active Surveil-
lance include: a biopsy GS 6, a PSA level 10 ng/mL, a PSA
density 0.2 ng/mL/cm3, and no more than two positive cores.
However, only patients with tumors of clinical stage T1c were
included for AS in this study. Multivariate logistic regression anal-
ysis was then performed to identify predictors of low-risk PCA. All
statistical tests were two-tailed and were performed using SPSS
version 20.0 software (SPSS Inc., Chicago, IL, USA). A P value< 0.05
was considered statistically signiﬁcant.
3. Results
The patient ages in this study ranged from 48 years to 74
years (mean ± standard deviation, 63.3 ± 6.2 years), and the
serum PSA levels at diagnosis ranged from 3.2 ng/mL to 21.7 ng/
mL (mean ± standard deviation, 6.0 ± 1.9 ng/mL). The medianbiopsy GS was 6 (range, 3e9). The mean interval between the
transrectal ultrasound-guided biopsy and the postbiopsy MRI was
22.0± 1.3 days (range, 2e32 days). In all patients, RP was per-
formed within 52 days (range, 6e52 days; median 21 days) after
MR imaging.
The pathological ﬁndings of the 177 patients with nonvisible
tumors on MRI (clinical stage T1c) before RP are shown in Table 1.
These pathological ﬁndings resulted in the upgrading of 49 (27.9%)
patients to a sum of GS 7 or more. One hundred and one (57.1%)
patients exhibited a tumor volume greater than 0.5 cc. The
numbers of patients with tumors of pathological stage T2 and T3 or
above were 126 (71.0%) and 51 (29.0%), respectively.
The clinicopathological ﬁndings in the pathological upgraded
group (N¼ 49) and the pathological nonupgraded group
(N¼ 128) are compared in Table 2. Both the average level of PSA
and the average PSA density were signiﬁcantly different between
the two groups (P< 0.01). Interestingly, the average number of
cores involved and the maximum core diameters were signiﬁ-
cantly higher in the pathological upgraded group compared with
the pathological nonupgraded group, even though the average GS
at biopsy were not signiﬁcantly different between the two groups
(P¼ 0.02 and P< 0.01, respectively). Furthermore, the biochem-
ical recurrence rate (BCR) was signiﬁcantly higher after the
follow-up period (mean, 29 months) in the pathological upgra-
ded group compared with the nonupgraded group (P< 0.01;
Table 2).
Of the 39 patients with tumors of clinical stage T1c who met the
criteria for AS, seven patients (17.9%) showed pathological GS
upgrading, and three patients (7.7%) were classiﬁed as pathological
stage T3 or above. However, of the 138 patients with tumors of
clinical stage T1c who did not meet the criteria for AS, 42 patients
(30.4%) showed pathological GS upgrading, and 48 patients (34.8%)
were classiﬁed as pathological stage T3 or above. Candidates who
did not meet the criteria for AS and who exhibited nonvisible tu-
mors on MRI had signiﬁcantly higher incidences of pathological
upgrading and upstaging compared with candidates who meet the
criteria for ASwith nonvisible tumors onMRI (P< 0.01 and P¼ 0.02,
respectively). Of the entire study cohort, nonvisible tumors on MRI
were detected in 177 patients (28.4%), whereas 446 patients (71.6%)
had visible tumors (Fig.1). No signiﬁcant differences in the extent of
pathological GS upgrading, staging classiﬁcations, or BCR rates
were observed between the two groups.
Using multivariate logistic regression analysis to predict the
development of low-risk PCA, both PSA level and PSA density were
signiﬁcantly associated with an increased likelihood for developing
low-risk PCA. However, tumor visibility on the preoperative MRI
scan did not exhibit this association (Table 3).
Table 2
Comparison of Clinicopathological Findings Between the Pathological Upgraded Group and the Nonupgraded Group from Analyses of Radical Prostatectomy Specimens from
Patients Preoperatively Classiﬁed as Clinical Stage T1c.
Pathological upgrading No pathological upgrading P
No. 49 128
Age (y) 63.6 (49e71) 63.1 (48e74) 0.45
Interval from biopsy to MRI (d) 21.8 (2e25) 22.1 (2e29) 0.32
DRE-positive ﬁnding (N) 6 (12.2) 13 (10.1) 0.09
PSA (ng/mL) 6.5 (3.5e19.3) 5.1 (3.2e21.7) <0.01
PSA density 0.20 (0.07e0.67) 0.15 (0.10e0.45) <0.01
Prostate volume (cc) 30.2 (16.4e64.5) 33.7 (14.8e71.3) 0.13
Biopsy ﬁndings
Gleason score 5.9± 0.7 5.8± 0.4 0.24
No. of involved cores 2.1± 3.3 1.6± 1.9 0.02
Maximal tumor diameter (mm) 19.2± 2.8 11.8± 1.7 <0.01
Final stage <0.01
T2 7 (14.3) 119 (92.9)
T3 42 (85.7) 9 (7.1)
Positive surgical margin 44 (89.8) 18 (10.2) <0.01
Tumor volume (cc) <0.01
0.5 13 (26.5) 88 (68.8)
>0.5 36 (73.5) 40 (31.2)
BCR (N) 11 (22.4) 6 (4.7) <0.01
Data are presented as n (%), mean (range), or mean± standard deviation.
BCR, biochemical recurrence; DRE, digital rectal examination; MRI, magnetic resonance imaging; PSA, prostate-speciﬁc antigen.
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Since the widespread use of PSA testing has dramatically
increased the number of low-risk PCA cases identiﬁed, more pre-
cise clinical stagingwould allow themost appropriate candidates to
proceed with AS. However, since clinical staging is still imperfect,
patients with PCAwho choose AS also take a calculated risk. Several
lines of evidence indicate that a signiﬁcant proportion of patients
who are suitable for AS, at least according to the most commonly
adopted criteria, have unfavorable PCA characteristics discovered if
they undergo RP.10,11 Klotz et al12 recently demonstrated that up to
50% of all patients who are treated after an initial period of obser-
vation develop BCR; this ﬁnding questions the ability of AS to
maintain the window of curability in patients who have low-risk
PCA characteristics at diagnosis.12 Conti et al13 reported that 28%
of all men who met the AS criteria also had GS upgrading, 21%
experienced extracapsular extension, and 11% had seminal vesicle
invasion at RP. To ensure that AS is used appropriately, providers
must more accurately predict the likelihood of progression in pa-
tients. In the context of accurate clinical staging, MRI is playing an
increasingly important role in the selection of suitable candidates
for AS.
In the present study, we collected data on nonvisible tumors on
MRI foci in both AS candidates and also in patients who were not
chosen for AS. Of all the patients found to have nonvisible tumorsFig. 1. Comparison of pathological ﬁndings between nonvisible tumor versus visible
tumor on magnetic resonance image. BCR, biochemical recurrence; GS, Gleason score.on MRI, 78% were not eligible for AS. We had hypothesized that
men with nonvisible tumors on MRI at the time of staging would
have more favorable pathologic features compared with men in
whom MRI-visible tumors were observed. Interestingly, however,
pathologic parameters such as GS upgrading, staging upgrading,
and BCR did not signiﬁcantly differ between the MRI-visible versus
the nonvisible tumor on MRI groups (Fig. 1). Guzzo et al14 reported
that a small but signiﬁcant percentage of men who are thought to
have low-risk, low-volume PCA at the time of clinical staging by
MRI are actually understaged and are more appropriate candidates
for immediate intervention. These results call into question the
clinical usefulness of MRI, especially in the context of evaluating the
characteristics of low-volume tumors. Roethke et al15 reported that
MRI was unable to detect tumors with diameters and volumes
smaller than 10 mm and 0.4 cm3, respectively. Moreover, MRI has
been shown to be unsuitable for visualizing tumor foci with a
maximum size of 0.3 cm; importantly, 3% of all tumors are sized
between 0.3 cm and 0.5 cm, whereas 13% are sized between 1 cm
and 0.5 cm. Volume-dependent detection has been shown to have a
detection rate of 4% for tumors less than 0.5 mL in volume; this rate
increased to 89% for tumors 2 mL or more in volume. Rosenkrantz
et al16 observed biological differences between tumors that were
detected by MRI and tumors that were missed by MRI. Desmo-
plastic stroma was present in all detected tumors, and the overall
detection of solid tumor growth had an odds ratio of 17.8. This
result highlights the importance of the formation of a discrete
nodule of continuous tumor growth to enable MRI detection. Given
these ﬁndings, the inability to visualize a known tumor byMRI may
indicate the lack of a distinct nodule of malignant glands encom-
passed by the tumor.16
In our study, of the 177 patients with nonvisible tumors on MRI,
76 (42.9%) exhibited a tumor volume greater than 0.5 cc in the ﬁnal
pathology examination. Several factors might contribute to the low
detection rate of tumors of relatively high volumes. First, central
gland and transitional gland tumors are considered more difﬁcult
to detect with MRI and would likely not have been observed.
Transitional zone tumors have also been shown to be difﬁcult to
distinguish from benign hyperplasia nodules, even though their
speciﬁc T2w image features have been recently described.17
Furthermore, the role of dynamic contrast-enhanced MRI in the
diagnosis of central gland tumors is limited. Padhani et al18
Table 3
Signiﬁcant Predictors of Low-risk Prostate Cancer According to Multiple Logistic
Regression Analysis.
Variable Odds ratio (95% CI) P
Age (y) 1.031 (0.843e3.117) 0.483
PSA 1.384 (1.103e2.011) 0.027
PSA density 1.294 (1.083e1.847) 0.031
Biopsy Gleason score
Gleason score 6 Reference
Gleason score> 6 0.818 (0.467e1.319) 0.095
% positive cores in the biopsy 0.955 (0.816e1.420) 0.305
No. of positive cores 0.913 (0.658e1.275) 0.123
MRI ﬁndings
Nonvisible tumor Reference
Visible tumor 0.895 (0.315e1.388) 0.092
CI, conﬁdence interval; MRI, magnetic resonance imaging; PSA, prostate-speciﬁc
antigen.
Prostate Int 3 (2015) 127e131130described a complete overlap in the enhancement characteristics
between cancer and benign prostatic hyperplasia; this high degree
of similarity between the two was explained by the increased
microvessel density in benign prostatic hyperplasia, which is similar
to that in cancer. Secondly, we did not exclude any cases based on
the delay between the biopsy and the MRI scan; thus, postbiopsy
hemorrhage may have inﬂuenced tumor detection in some cases.
However, as shown in Table 2, the interval from biopsy to MRI in
our study was relatively short compared with other studies.19,20 No
consensus has yet been reached regarding the optimal timing of
MRI for acute staging. In our previous report,21 a signiﬁcant nega-
tive correlation between the amount of postbiopsy hemorrhage
and the time from the biopsy to the MRI scan was observed, even
though no signiﬁcant differences in cancer localization were
observed between the MRI data and the ﬁnal pathology data.
Qayyum et al19 suggested that MRI and MR spectroscopic imaging
should be conducted at least 8 weeks postbiopsy since hemor-
rhaging was found to be decreased by that time. However, hem-
orrhages do not actually appear to interfere with the ability of MRI
to detect tumor characteristics since no signiﬁcant difference was
observed in the interval from biopsy to MRI between the patho-
logical upgraded and nonupgraded groups. Future studies are
needed to clarify the precise effects of postbiopsy hemorrhage on
the accuracy of MRI-based diagnostic approaches.
Most previous studies have includedASpatientswhounderwent
MRI.14,22,23 Guzzo et al14 reported that the extent of tumor visibility
on the T2W-MRI scans was not predictive of the pathologic features
of RP specimens, and that T2W-MRI scans could not provide addi-
tional useful information for candidates undergoing AS. Moreover,
Ploussard et al24 showed that standardMRI was not a useful marker
to improve the selection for AS when an extended 21-core biopsy
scheme was used. D’Amico et al25 found that preoperative endor-
ectal MRI imparted prognostic information that was only incre-
mentally important comparedwith standard clinical factors such as
stage, GS, and PSA level; however, this study only included patients
with intermediate to high-risk disease. However, prostate MRI has
been shown to have a signiﬁcant value for the identiﬁcation of
extracapsular extension and seminal vesicle invasion.26,27 These
beneﬁts were primarily detected in patients with intermediate or
high risk PCA.28 Rais-Bahrami et al29 found that multiparametric
MRI more accurately detected and characterized tumors in patients
with disease of GS 7 or higher. The 2013 NCCN guideline recom-
mends pelvic computed tomography or MRI scanning if T3 or T4
disease is present, or if T1 or T2 disease is present and a nomogram
indicates that the chance of lymphnode involvement is greater than
20%; however, staging studies may not be cost-effective until the
chance of lymph node involvement reaches 45%.30 From these re-
sults, the role of prostate MRI in the detection of low-risk PCA is notyet clear. To elevate the accuracy of staging low-risk PCA, additional
MR techniques, such as MR spectroscopy, will likely be necessary.
The present study did have several limitations. Firstly, our study
had a retrospective design and a relatively small sample size.
Moreover, our study may have been subject to some degree of se-
lection bias since only patients who underwent RP were enrolled.
In addition, our data were collected at a single institution; thus, our
study is also subject to the limitations and biases of any analysis
based on treatment outcomes from a single center. Secondly, as we
previously mentioned, the length of time from the biopsy to the
MRI scan was not factored into our study analysis. This may have
affected our results since hemorrhages are more likely to interfere
withMRI detection in patients with shorter intervals from biopsy to
MRI. However, our multiparametric MRI protocol including pre-
contrast T1WI can overcome this limitation because areas of
hemorrhage will also be characteristically hyper-intense on T1WI.
Even though cancer foci were not visualized with postbiopsy
MRI, pathological tumor volumes and the extent of GS upgrading
were relatively high in our study. Therefore, nonvisible tumors on
multiparametric MRI do not appear to predict the development of
low-risk PCA.
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